An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.
The recording will be accessible starting January 10, 2022, at 4:00 a.m. PT under the 'Events & Presentations' section on the company’s website for a duration of at least 30 days.
Xencor currently has 22 candidates in clinical development utilizing its XmAb® technology.
Positive
None.
Negative
None.
MONROVIA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.
The on-demand recording will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com beginning Monday, January 10, 2022 at 4:00 a.m. PT and will be available on the website for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
